Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$4.13 - $6.79 $39,111 - $64,301
9,470 Added 55.4%
26,565 $164,000
Q1 2024

Apr 25, 2024

BUY
$4.89 - $7.65 $83,594 - $130,776
17,095 New
17,095 $86,000
Q3 2023

Nov 01, 2023

BUY
$6.71 - $7.92 $54,109 - $63,866
8,064 New
8,064 $57,000
Q1 2023

Apr 27, 2023

BUY
$7.94 - $11.84 $184,454 - $275,055
23,231 Added 57.96%
63,313 $528,000
Q4 2022

Feb 02, 2023

BUY
$10.5 - $14.2 $420,861 - $569,164
40,082 New
40,082 $460,000
Q2 2022

Aug 03, 2022

BUY
$7.89 - $17.88 $166,281 - $376,821
21,075 Added 31.84%
87,260 $923,000
Q1 2022

May 02, 2022

BUY
$11.56 - $19.76 $714,003 - $1.22 Million
61,765 Added 1397.4%
66,185 $1.08 Million
Q4 2021

Feb 23, 2022

SELL
$11.18 - $15.46 $528,981 - $731,489
-47,315 Reduced 91.46%
4,420 $61,000
Q3 2021

Oct 28, 2021

SELL
$14.21 - $17.65 $18,103 - $22,486
-1,274 Reduced 2.4%
51,735 $841,000
Q2 2021

Aug 12, 2021

BUY
$9.5 - $17.24 $124,811 - $226,499
13,138 Added 32.95%
53,009 $838,000
Q1 2021

Apr 26, 2021

SELL
$7.37 - $13.61 $1.55 Million - $2.87 Million
-210,641 Reduced 84.08%
39,871 $0
Q4 2020

Feb 02, 2021

BUY
$3.37 - $8.61 $756,207 - $1.93 Million
224,394 Added 859.15%
250,512 $1.87 Million
Q3 2020

Oct 14, 2020

BUY
$3.43 - $5.53 $53,778 - $86,704
15,679 Added 150.2%
26,118 $89,000
Q2 2020

Jul 13, 2020

BUY
$1.9 - $5.61 $19,834 - $58,562
10,439 New
10,439 $49,000
Q1 2020

Apr 29, 2020

SELL
$1.6 - $4.11 $4,644 - $11,931
-2,903 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$1.59 - $3.45 $4,615 - $10,015
2,903 New
2,903 $10,000
Q1 2019

Apr 18, 2019

SELL
$7.38 - $9.72 $27,173 - $35,789
-3,682 Closed
0 $0
Q4 2018

Jan 16, 2019

SELL
$6.51 - $9.6 $23,540 - $34,713
-3,616 Reduced 49.55%
3,682 $29,000
Q3 2018

Oct 23, 2018

BUY
$5.52 - $7.99 $40,284 - $58,311
7,298 New
7,298 $55,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.